Sign in to continue:

Saturday, March 7th, 2026

Laekna, Inc. Announces Board Meeting to Approve 2025 Annual Results on March 18, 2026 1

Key Points for Investors

  • Board Meeting Date: Laekna, Inc. will hold its Board of Directors meeting on Wednesday, 18 March 2026.
  • Purpose of Meeting: The primary agenda is to consider and approve the annual results of Laekna, Inc. and its subsidiaries for the financial year ended 31 December 2025.
  • Results Announcement: The meeting will also cover the publication of the approved annual results, which is a key disclosure event for investors.

Potentially Price Sensitive Information

  • Annual Results Approval: The upcoming approval and subsequent publication of the 2025 annual financial results is a critical event. Investors should note that any significant financial developments or performance indicators revealed during the announcement could have a material impact on Laekna, Inc.’s share price.
  • Shareholder Awareness: Shareholders and prospective investors are advised to monitor the outcome of this meeting closely, as annual results often contain information on revenue, profit, loss, strategic developments, and outlook, all of which are highly relevant to the company’s valuation and share price trajectory.

Board Composition

As of the date of this announcement, the Board of Directors of Laekna, Inc. is comprised of the following members:

  • Executive Directors: Dr. LU Chris Xiangyang (Chairman), Ms. XIE Ling, Dr. GU Xiang-Ju Justin
  • Non-executive Directors: Dr. WANG David Guowei, Mr. SUN Yuan
  • Independent Non-executive Directors: Dr. YIN Xudong, Dr. LI Min, Mr. ZHOU Jian

What Should Shareholders Do?

  • Mark the date (18 March 2026) for the board meeting and watch for the subsequent release of the annual results.
  • Review the company’s financial performance for 2025 as soon as the results are published to assess any potential impact on your investment.
  • Consider potential volatility around the time of results publication, as market participants react to the company’s reported performance and any forward-looking statements.

Disclaimer: This article is for informational purposes only and should not be considered investment advice. Investors are encouraged to perform their own due diligence and consult with a qualified financial advisor before making any investment decisions. The content herein is based on a board meeting announcement by Laekna, Inc. and does not reflect any actual financial results or forecasts.

View LAEKNA-B Historical chart here



Hansoh Pharmaceutical’s Aumolertinib Mesylate Tablets Approved in EU as Monotherapy for Advanced EGFR-Mutated NSCLC 1

Hansoh Pharmaceutical Group – EU Approval for Aumolertinib Mesylate Tablets Hansoh Pharmaceutical Group Receives Landmark EU Approval for Aumolertinib Mesylate Tablets as Monotherapy in Advanced NSCLC Key Highlights for Investors European Union (EU) Approval:...

BlackRock Discloses Purchase of ENN Energy Holdings Shares Amid Privatisation Scheme (Feb 2026)

Detailed Report BlackRock, Inc., a globally renowned investment firm and a Class (6) associate of ENN Energy Holdings, has significantly increased its stake in the company. On 16 February 2026, BlackRock purchased 1,078,507 shares...

China Starch Holdings Issues 2025 Profit Warning Amid Revenue Decline and Industry Challenges

China Starch Holdings Issues Profit Warning: Significant Decline in Revenue and Profit for 2025 Key Highlights Substantial Decrease in Profit: China Starch Holdings Limited expects a significant drop in profit before taxation—approximately 64% lower...

   Ad